BR112022008037A2 - Agonistas de 5-ht2a para uso no tratamento da depressão - Google Patents

Agonistas de 5-ht2a para uso no tratamento da depressão

Info

Publication number
BR112022008037A2
BR112022008037A2 BR112022008037A BR112022008037A BR112022008037A2 BR 112022008037 A2 BR112022008037 A2 BR 112022008037A2 BR 112022008037 A BR112022008037 A BR 112022008037A BR 112022008037 A BR112022008037 A BR 112022008037A BR 112022008037 A2 BR112022008037 A2 BR 112022008037A2
Authority
BR
Brazil
Prior art keywords
ht2a
treatment
agonists
relates
depression
Prior art date
Application number
BR112022008037A
Other languages
English (en)
Inventor
Langgaard Kristensen Jesper
Asbjorn Jensen Anders
Märcher-Rorsted Emil
Leth-Petersen Sebastian
Original Assignee
Lophora ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lophora ApS filed Critical Lophora ApS
Publication of BR112022008037A2 publication Critical patent/BR112022008037A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)

Abstract

AGONISTAS DE 5-HT2A PARA USO NO TRATAMENTO DA DEPRESSÃO. A presente invenção refere-se a agonistas de receptores de serotonina 5-HT2A e seus usos médicos. Em um aspecto, a invenção se refere a agonistas de 5-HT2A de fórmula (I). No segundo aspecto, a invenção se refere a agonistas de 5-HT2A seletivos de fórmula (II). Em outro aspecto, a invenção se refere a agonistas de 5-HT2A/5-HT2C mistos de fórmula (III). Ainda em outro aspecto, a invenção se refere a agonistas de 5-HT2A para uso no tratamento de um transtorno depressivo, mais particularmente um agonista de 5-HT2A para uso no tratamento da depressão resistente ao tratamento.
BR112022008037A 2019-11-07 2020-11-06 Agonistas de 5-ht2a para uso no tratamento da depressão BR112022008037A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19207578 2019-11-07
US17/090,457 US11246860B2 (en) 2019-11-07 2020-11-05 5-HT2A agonists for use in treatment of depression
PCT/EP2020/081357 WO2021089824A1 (en) 2019-11-07 2020-11-06 5-ht2a agonists for use in treatment of depression

Publications (1)

Publication Number Publication Date
BR112022008037A2 true BR112022008037A2 (pt) 2022-07-12

Family

ID=68502828

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022008037A BR112022008037A2 (pt) 2019-11-07 2020-11-06 Agonistas de 5-ht2a para uso no tratamento da depressão

Country Status (21)

Country Link
US (3) US11246860B2 (pt)
EP (1) EP3962601B1 (pt)
JP (1) JP7566021B2 (pt)
CN (1) CN114761083B (pt)
AU (1) AU2020379225B2 (pt)
BR (1) BR112022008037A2 (pt)
CA (1) CA3156513A1 (pt)
DK (1) DK3962601T3 (pt)
ES (1) ES2953926T3 (pt)
FI (1) FI3962601T3 (pt)
HR (1) HRP20230856T1 (pt)
HU (1) HUE062369T2 (pt)
IL (1) IL292585B2 (pt)
LT (1) LT3962601T (pt)
MA (1) MA55821B1 (pt)
MD (1) MD3962601T2 (pt)
PL (1) PL3962601T3 (pt)
PT (1) PT3962601T (pt)
SI (1) SI3962601T1 (pt)
WO (1) WO2021089824A1 (pt)
ZA (1) ZA202204809B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11246860B2 (en) * 2019-11-07 2022-02-15 Lophora ApS 5-HT2A agonists for use in treatment of depression
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
KR20260044248A (ko) 2020-08-18 2026-04-01 사이빈 아이알엘 리미티드 치료 펜에틸아민 조성물 및 사용 방법
JP2024516827A (ja) 2021-04-30 2024-04-17 マインド メディシン， インコーポレイテッド Ｌｓｄ塩結晶形態
WO2022234010A1 (en) * 2021-05-06 2022-11-10 Lophora ApS Acid addition salts of (s)-3-(2,5-dimethoxy-4-(trifluoromethyl)phenyl)piperidine and (s)-3-(2-methoxy-5-(methylthio)-4-(trifluoromethyl)phenyl)piperidine, specific polymorphs thereof and methods for their manufacture
IL309842A (en) * 2021-07-26 2024-02-01 Univ Louisiana State Compounds and methods for treating situations where the response depends on 5-HT2
AU2022331315B2 (en) 2021-08-19 2025-10-16 Definium Therapeutics US, Inc. Lyophilized orally disintegrating tablet formulations of d-lysergic acid diethylamide for therapeutic applications
WO2024181024A1 (ja) * 2023-03-02 2024-09-06 本田技研工業株式会社 組成物
WO2025008804A1 (en) * 2023-07-06 2025-01-09 M – Path Biopharma Ltd. Combination therapy for amelioration of side effects of estrogen receptor inhibitor treatment
WO2026073180A2 (en) * 2024-09-30 2026-04-02 Revolution Medicines, Inc. Synthesis of ras inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608101B1 (en) 2000-06-20 2003-08-19 Atherogenics, Inc. 1, 3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
US11246860B2 (en) * 2019-11-07 2022-02-15 Lophora ApS 5-HT2A agonists for use in treatment of depression

Also Published As

Publication number Publication date
HRP20230856T1 (hr) 2023-11-10
US11246860B2 (en) 2022-02-15
US20210137908A1 (en) 2021-05-13
MD3962601T2 (ro) 2023-10-31
US11642336B2 (en) 2023-05-09
DK3962601T3 (da) 2023-09-04
WO2021089824A1 (en) 2021-05-14
US11633390B2 (en) 2023-04-25
HUE062369T2 (hu) 2023-10-28
SI3962601T1 (sl) 2023-10-30
ES2953926T3 (es) 2023-11-17
FI3962601T3 (fi) 2023-08-09
CA3156513A1 (en) 2021-05-14
MA55821A (fr) 2022-05-04
PT3962601T (pt) 2023-08-28
CN114761083B (zh) 2024-02-13
MA55821B1 (fr) 2023-08-31
EP3962601B1 (en) 2023-05-31
CN114761083A (zh) 2022-07-15
JP7566021B2 (ja) 2024-10-11
US20210330658A1 (en) 2021-10-28
IL292585A (en) 2022-06-01
JP2023501275A (ja) 2023-01-18
AU2020379225A1 (en) 2022-05-26
IL292585B2 (en) 2023-08-01
PL3962601T3 (pl) 2023-10-09
US20220062257A1 (en) 2022-03-03
ZA202204809B (en) 2022-11-30
IL292585B1 (en) 2023-04-01
AU2020379225B2 (en) 2026-03-26
EP3962601A1 (en) 2022-03-09
LT3962601T (lt) 2023-09-11

Similar Documents

Publication Publication Date Title
CO2023011071A2 (es) Agonistas del receptor gpcr, composiciones farmacéuticas que los comprenden y métodos para su uso
CR20200403A (es) Macrociclos como moduladores del regular de conductancia transmenbrana de la fibrosis quística, composiciones farmacéuticas de estos, su uso en el tratamiento de la fibrosisquística y procesos para elaborarlos
CL2012001422A1 (es) Compuestos derivados de sulfonil benzamidas sustituidas, inductores de apoptosis con selectividad por bcl-2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CL2018003265A1 (es) Modulares del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
BR112015018092A2 (pt) moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
CL2009000245A1 (es) Compuestos derivados de heterociclil piridinilo, con actividad moduladora del receptor 5-ht6; composicion farmaceutica que los comprende y su uso para tratar la esquizofrenia, ansiedad, migrana, depresion, entre otros.
BR112015018094A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
UY35029A (es) Derivados tricíclicos de quinolinas y de quinoxalinas
BR112015018087A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
BR112018004532A2 (pt) uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos
BR112015018089A2 (pt) moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
CO7101245A2 (es) Compuestos de benzaldehído sustituidos y métodos para su uso en incrementar la oxigenación del tejido
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
MX378386B (es) Composiciones antiirritantes sinérgicas de taurina y aloe.
MX2018005544A (es) Uso de agonistas del receptor tipo toll- 8 (tlr8) para tratar cancer.
UY36654A (es) Azabenzimidazoles con propiedades moduladoras del receptor ampa y composiciones farmacéuticas que los contienen
BR112019003811A2 (pt) composição farmacêutica, método para aumentar os níveis plasmáticos de antagonista do receptor de nmda em um sujeito que precisa do mesmo, método para tratar uma doença ou transtorno em um sujeito que precisa do mesmo e uso da composição
BR112017003346B8 (pt) Derivados de pirazolopiridina, seus usos, e composição farmacêutica
ECSP21090478A (es) Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b
LT3962601T (lt) 5-ht2a agonistai, skirti panaudoti depresijos gydymui
CL2009000084A1 (es) Compuestos derivados de sulfonamida sustituida, moduladores de receptores de bradiquinina; composicion farmaceutica que contiene a los compuestos; y uso en el tratamiento del dolor agudo, neuropatico o cronico, entre otros.
CL2007001779A1 (es) Compuestos triciclicos, con afinidad superior por los receptores de melatonina; composicion farmaceutica; util para la profilaxis o tratamiento de la enfermedad del sueno y compuestos intermediarios.
CL2015003761A1 (es) Derivados de etinil como antagonistas de receptor metabotrópico de glutamato.
CY1119871T1 (el) Στερεη μορφη αλατος της aλφa-6-mpeg6-o- υδροξυκωδονης ως αγωνιστες οπιοειδων και χρησεις αυτων
CL2019003501A1 (es) Compuestos.

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]